Functional experiments demonstrated that THOR hypermethylation is a crucial regulatory event for hTERT transcriptional activation in BC and can be demethylated in a targeted fashion, thus constituting a promising biomarker and therapeutic target for BC. Here, THORLNC is linked to breast cancer.